From: Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
Score | No. of patients (relapses) | Univariate comparisons | Multivariable comparisons | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
CTS + signature vs CTS | CTS + signature | ||||||||||
LRχ2 | p Value | HR (95% CI) | P diff | C-index (SE) | ΔLRχ2 | p Value | HR (95% CI) | P diff | C-index (SE) | ||
0–10 years |  | ||||||||||
 CTS | 314 (59) | 48.7 | < 0.001 | 2.16 (1.79–2.62) | – | 0.674 (0.018) | – | – | – | – | – |
 10-Year signature | 28 | < 0.001 | 1.98 (1.54–2.55) | Reference | 0.671 (0.026) | 7.9 | 0.005 | 1.49 (1.13–1.96) | Reference | 0.709 (0.021) | |
 Early signature | 33.4 | < 0.001 | 2.06 (1.62–2.61) | 0.334 | 0.678 (0.024) | 10.3 | 0.001 | 1.55 (1.19–2.02) | 0.48 | 0.711 (0.020) | |
 Late signature | 18.1 | < 0.001 | 1.72 (1.34–2.20) | 0.000 | 0.642 0(.029) | 4.3 | 0.037 | 1.33 (1.02–1.74) | 0.004 | 0.700 (0.022) | |
0–5 years |  | ||||||||||
 CTS | 314 (26) | 29 | < 0.001 | 2.04 (1.53–2.74) | – | 0.679 (0.023) | – | – | – | – | – |
 10-Year signature | 14.1 | < 0.001 | 2.05 (1.41–2.98) | 0.833 | 0.678 (0.037) | 3.2 | 0.073 | 1.46 (0.97–2.19) | 0.77 | 0.712 (0.029) | |
 Early signature | 14.9 | < 0.001 | 2.00 (1.42–2.81) | Reference | 0.672 (0.035) | 2.8 | 0.096 | 1.40 (0.95–2.06) | Reference | 0.705 (0.028) | |
 Late signature | 8.9 | 0.003 | 1.77 (1.22–2.57) | 0.138 | 0.648 (0.042) | 1.7 | 0.19 | 1.31 (0.87–1.97) | 0.65 | 0.705 (0.031) | |
5–10 years |  | ||||||||||
 CTS | 270 (33) | 19.8 | < 0.001 | 1.84 (1.33–2.54) | – | 0.657 (0.026) | – | – | – | – | – |
 10-Year signature | 13.9 | < 0.001 | 1.93 (1.37–2.72) | 0.027 | 0.663 (0.036) | 4.8 | 0.028 | 1.53 (1.05–2.22) | 0.14 | 0.696 (0.030) | |
 Early signature | 18.6 | < 0.001 | 2.11 (1.52–2.94) | 0.091 | 0.681 (0.032) | 8 | 0.005 | 1.70 (1.19–2.43) | 0.14 | 0.708 (0.028) | |
 Late signature | 9.3 | 0.002 | 1.68 (1.21–2.34) | Reference | 0.636 (0.038) | 2.7 | 0.099 | 1.36 (0.95–1.94) | Reference | 0.686 (0.031) |